Drugs / VMP001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01157897 | Jul 2010 → Jan 2012 | Plasmodium vivax malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMP001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01157897 ↗ |
| Known as | Plasmodium vivax malaria protein 001 | “Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B” NCT01157897 ↗ |
| Modality | Protein / enzyme biologic | “recombinant protein VMP001, a Plasmodium vivax circumsporozoite (CS) protein based vaccine” NCT01157897 ↗ |
| Route | Intramuscular | “VMP001 Administered Intramuscularly” NCT01157897 ↗ |